Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2005

View Archived Issues

New data on the effects of valopicitabine in hepatitis C

ScFvMA2-TAP: A fusion protein with clot targeting, antiplatelet and fXa inhibitory properties

A novel OM4 Fab antibody displays antithrombotic efficacy with minimal bleeding risk in vivo

Novel conjugate for liver fibrosis

PGX-200097: targeted to treat positive and negative symptoms of schizophrenia

DOR plans U.S. and E.U. submissions for orBec

Canadian clearance for pivotal trial of BST-CarGel

JNJ-5234801 exerts beneficial effects in rodent models of anxiety and alcoholism

Transgene and IAVI sign manufacturing agreement

New TB vaccine begins clinical trials

Preclinical data for ReN-001 stem cell line for stroke

Long-term continuous abstinence data for CYT002-NicQb

Phase II trial assesses leuprolide as adjuvant for melanoma vaccine

Celltrion obtains Asian commercialization rights for IGN-311

Inex to spin off Targeted Immunotherapy assets

Vernalis to acquire Cita NeuroPharmaceuticals

Galenea receives SBIR to develop siRNA products for influenza

PBD-polyamide conjugate interferes with gene expression in NIH3T3 cells

L-117: A novel 5-fluoracil analogue with reduced toxicity

Three new breast cancer trials begin for Modrenal

PF-941222: A novel FAK inhibitor developed by Pfizer

Xenazine receives French marketing approval

BioMimetic's GEM-21S approved for periodontal bone defects

Vantas approved in Denmark for advanced prostate cancer

Effexor XR approved for adults with panic disorder

FDA Advisory Committee confirms safety of Tamiflu in children

New therapeutic agents for skin disorders disclosed in recent patents

Companies patent new agents with possible application in the treatment of neurological disorders

Histamine H1 receptor antagonists for insomnia emerge from Neurocrine R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...